Roizman reshaped the field of virology through his work on the herpes simplex virus, laying the groundwork for efforts to ...
Lucra’s plug-and-play SDK enables brands to launch peer-to-peer challenges, tournaments, and live competitions that drive ...
Pharmaceutical Technology on MSN
FDA issues complete response letter to Replimune’s RP1 for melanoma
Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
You may not have heard of Helen Edwards yet, but the 74-year-old grandmother could save your life. Her story went viral after ...
The prevalence of invasive bacterial infection in young febrile infants is estimated at 1%–4%, with the highest rates in ...
A stone tomb near Paris held generations of dead, but the people buried there did not all belong to the same world. That is ...
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
A 2026 consumer information overview addressing Herpafend ingredient safety profiles, potential drug interaction considerations, supplement claim context, and what HSV-1 and HSV-2 wellness consumers ...
Delve Bio announces data showing Delve Detect enables neurologists to treat CNS infections when conventional testing fails at AAN Annual Meeting ...
What started as a late-40s idea that most biotech experts would have called impossible is now a $7.9 billion company. Built ...
Opinion
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program. Replimune Group received a complete ...
Malawi’s anti-corruption chief is accused of using confidential case files to pressure a parliamentary probe into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results